An Overview and Management of Multiple Chronic Conditions 2020
DOI: 10.5772/intechopen.91010
|View full text |Cite
|
Sign up to set email alerts
|

Enkephalin Therapy Improves Relapsing-Remitting Multiple Sclerosis

Abstract: Multiple sclerosis (MS) is accompanied by decreases in serum endogenous enkephalin/endorphins and alterations in inflammatory cytokines. This retrospective analysis of serum levels was conducted in 53 patients with established relapsing-remitting MS treated with the disease-modifying therapies (DMT) glatiramer acetate, dimethyl fumarate or with the biotherapeutic low dose naltrexone (LDN) to elevate enkephalins, an off-label alternative. Opioid growth factor (OGF), an inhibitory endogenous opioid involved in m… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 80 publications
(136 reference statements)
0
2
0
Order By: Relevance
“…Naltrexone is a general opioid receptor antagonist used to treat alcohol and opioid addiction at 50 mg (Raknes & Småbrekke, 2017; Toljan & Vrooman, 2018). In contrast, LDN at a dosage of <5 mg/day has been shown to have beneficial effects on autoimmune pathologies such as Crohn's, fibromyalgia, and rheumatoid arthritis (Lie et al., 2018; Patel et al., 2020; Toljan & Vrooman, 2018; Younger et al., 2014; Zagon & McLaughlin, 2017, 2018). In EAE, LDN has been shown to reduce clinical symptomatology through the modulation of endogenous opioid signaling (Ludwig et al., 2017, 2018).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Naltrexone is a general opioid receptor antagonist used to treat alcohol and opioid addiction at 50 mg (Raknes & Småbrekke, 2017; Toljan & Vrooman, 2018). In contrast, LDN at a dosage of <5 mg/day has been shown to have beneficial effects on autoimmune pathologies such as Crohn's, fibromyalgia, and rheumatoid arthritis (Lie et al., 2018; Patel et al., 2020; Toljan & Vrooman, 2018; Younger et al., 2014; Zagon & McLaughlin, 2017, 2018). In EAE, LDN has been shown to reduce clinical symptomatology through the modulation of endogenous opioid signaling (Ludwig et al., 2017, 2018).…”
Section: Introductionmentioning
confidence: 99%
“…In EAE, LDN has been shown to reduce clinical symptomatology through the modulation of endogenous opioid signaling (Ludwig et al., 2017, 2018). The treatment of mice with 0.1 mg/kg LDN daily resulted in the restoration of serum levels of [Met] 5 ‐enkephalin (termed opioid growth factor (OGF)), which are reduced in both MS and EAE (Ludwig et al., 2017; Patel, Zagon, et al., 2020). In addition to restoring OGF levels in serum, LDN altered expression of both pro‐ (IFNγ) and anti‐inflammatory (IL‐10) cytokines in mice with EAE (Ludwig et al., 2018).…”
Section: Introductionmentioning
confidence: 99%